Gene Query: GLB1L2

Dataset Description Geneva Score
Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer 66.72
Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma 47.19
Nonpregnant and term pregnant human myometrial tissues 46.72
Transcriptomic profiles of nonpregnant and term pregnant human myometrial tissues 46.72
Global modulation of signaling pathways by SARM RAD140 in AR/ER+ breast cancer xenografts 46.36
Cancer avatars derived from genetically engineered pluripotent stem cells allow for longitudinal assessment of tumor development 43.92
Diverse Compounds from Pleuromutilin Lead to a Thioredoxin Inhibitor and Inducer of Ferroptosis 34.69
PHF20 readers link methylation of histone H3K4 and p53 with H4K16 acetylation 32.98
Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma: RNA-sequencing of PEL cell lines during KSHV reactivation 31.0
Differential gene expression by suppression of either SOX2 or TP63 in KYSE70 human esophageal squamous carcinoma cell line. 30.33
The m 6 A-methylase complex recruits TREX and regulates mRNA export. 26.91
Discovering the anti-cancer potential of non-oncology drugs by systematic PRISM profiling 26.21
The SUMO Pathway as a Therapeutic Option in Pancreatic Cancer 25.73
Epigenetic silencing of the tumor suppressor RASSF4 favors multiple myeloma progression 25.14
Quantitative Analysis of PPARD Transcriptomes in Colon Cancer Cells by Next Generation Sequencing (NGS) 24.74
RNA-seq in HT-29 colorectal cancer cells after F. nucleatum treatment 24.19
Gene expression changes upon drug withdrawal (A375/451Lu cell lines) 24.18
G-quadruplex structures mark human regulatory chromatin 23.02
A novel lncRNA lncRNA-AF339830 promotes colorectal carcinogenesis and glucose metabolism by stabilizing and specifying the transcription modification pattern of c-Myc [RNA-Seq] 22.7
A novel lncRNA lncRNA-AF339830 promotes colorectal carcinogenesis and glucose metabolism by stabilizing and specifying the transcription modification pattern of c-Myc 22.7
RNA-seq of YB5 and MCF7 treated with different doses of decitabine 21.27
Supraphysiological Androgens Repress Prostate Cancer Growth and Induce DNA Damage Augmented by PARP Inhibition 20.58
LncRNA NMR knockdown and overexpression in esophageal squamous cell carcinoma cell lines 20.46
Identification of the O-GlcNAc-regulated alternative splicing events by performing RNA sequencing on HeLa cells with altered O-GlcNAc level. 19.79
Forkhead domain mutations in FOXA1 drive prostate cancer cell progression 19.22
RNA-seq in LNCaP cell line overexpressing WT or mutant FOXA1 19.22
S-adenosyl-methionine treatment selectively block liver cancer cell lines transformation and invasiveness by alterations of cancer- and invasion specific transcriptome and methylome (RNA-Seq) 19.11
S-adenosyl-methionine treatment selectively block liver cancer cell lines transformation and invasiveness by alterations of cancer- and invasion specific transcriptome and methylome 19.11
Dtx3L and Androgen Signaling in Prostate Cancer 19.07
Disease-associated mutation in SRSF2 misregulates splicing by altering RNA binding affinities 18.51
The impact of pro-inflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes 18.45
The Wnt/β-catenin-signaling pathway is modulated by androgen ablation therapy for advanced clinical prostate cancer and contributes to androgen independent cell growth 17.72
Nutritional control of protein translation 15.21
RNA expression following TMPRSS11B overexpression or depletion 15.09
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination (RNAseq) 14.87
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination 14.87
Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-FU-Mediated Cytotoxicity in Multiple Human Cancer Types 14.67
The inhibitory effect of TIAM1 on TAZ transcriptional activity and TIAM1 differentially expressed genes 13.98
List of TIAM1 differentially expressed genes in SW620 cells [RNA-seq] 13.98
The landscape of alternative splicing in aggressive prostate cancers 13.91
Whole transcriptome splicing analysis in isogenic lung epithelial and adenocarcinoma cell lines with or without a recurrent splicing factor mutation, U2AF1 (S34F) 13.77
Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells 13.73
Gene expression profiling study by RNA-seq for identifying genes associated with epithelial-mesenchymal transition and acquired resistance to ALK inhibitors 13.36
Epithelial-mesenchymal transition and acquired resistance to ALK inhibitors 13.36
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator 13.18
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator [RNA-seq] 13.18
Gene expression profiling of LNCaP cells following shRNA-mediated knockdown of TMEFF2 and growth in presence and absence of dihydrotestosterone 13.14
Knockout of miR-221 and miR-222 reveals overlapping and specific function between paralogous miRNAs 13.1
Sequencing-based analyses characterize a tumor suppressive role of mir-1271 repressed by DNA hypermethylation in gastric cancer 12.76
SAM68 is required for regulation of Pumilio by the NORAD long noncoding RNA 12.64
Response of HEK293 Freestyle cells to 36 h of culture in Zn(II)-depleted Freestyle medium 12.35
TMED9-gated CNIH4 and TGFa signaling promotes pro-metastatic states in human primary colon cancer cells 12.25
DDX3X regulation of global translation is impaired by medulloblastoma-associated mutations [RNA-Seq] 12.03
DDX3X regulation of global translation is impaired by medulloblastoma-associated mutations 12.03
Transcriptional responses of human insulinoma cells to acute cytokine exposure 11.93
Functional characterization of RNA-binding protein IMP2 in primary Glioma cell lines [HTS] 11.91
Functional characterization of RNA-binding protein IMP2 in primary Glioma cell lines 11.91
Modeling the MYC-driven normal-to-tumour switch in breast cancer. 11.78
Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo 11.69
Comparing gene expression in iPSC derived RPE from control and AMD donors 11.47
Dynamics of Proteo-Transcriptomic Response to HIV-1 Infection 11.2
Control of prostate tumour growth by the long non-coding RNA GHSROS (LNCaP) 11.19
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma (RNA-Seq) 11.1
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma 11.1
Transcripotome analysis of different locations of hair follicles (bulb, bulge) in androgenetic alopecia 10.79
Molecular Signatures Associated with ZIKV Exposure in Human Cortical Neural Progenitors 10.71
Effect of TUNAR silencing and GSK3 inhibition on human b-cell transcriptome 10.7
KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis [RNA-Seq] 10.63
KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis 10.63
RNA-seq analysis of SKMEL28 melanoma cells following DIRC3 and IGFBP5 ASO knockdown 10.53
Expression profile of LNCaP/AR cells with or without HNF4G expression grown for long term in charcoal stripped-serum (CSS) media 10.33
An acquired vulnerability of drug resistant melanoma with therapeutic potential 10.32
RNA Seq data: A375, A375R, A375DR vorinostat treated, and biopy samples from patients pre- and post- treated with Vorinostat 10.32
Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance 10.29
An siRNA screen identifies CHD4 as a target for epigenetic therapy 10.21
Over expression of Receptor Activity Modifying Protein 2 in HEK293T cells 10.19
Leukodystrophy-associated POLR3A mutations down-regulate the RNA polymerase III transcript and important regulatory RNA BC200 10.03
Effect of Hotair overexpression in human breast cancer cell lines 9.9
Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation I 9.87
Gene expression analysis of BRD4 knockdown in HT-29 and HCT116 cells 9.61
Novel Targeting of Transcription and Metabolism in Glioblastoma 9.54
Tracking of dCas9-methyltransferase footprints 9.49
Disease modelling of core pre-mRNA splicing factor haploinsufficiency 9.48
ZBTB10 binds the telomeric variant repeat TTGGGG and interacts with TRF2 9.42
ZBTB10 binds the telomeric variant repeat TTGGGG and interacts with TRF2 [RNA-Seq] 9.42
Paclitaxel plus Cirmtuzumab Achieves Greater Clearance of Patient-derived Xenografts By Targeting ROR1+ Breast Cancer Stem Cells 9.38
SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival 9.35
Role for citron kinase in prostate cancer growth 9.22
RNA-seq of human aneuploid cell lines with Trisomy 21 9.2
Uridilation by TUT4/7 restricts retrotransposition of human Line-1s 9.19
WRN knockout effects upon gene expression in SW48 and OVK18 8.98
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer (BRD4_JQ1_RNA-seq) 8.88
A novel lncRNA lncRNA-AK096729 promotes colorectal carcinogenesis and glucose metabolism by stabilizing and specifying the transcription modification pattern of c-Myc 8.7
Global analysis of alternative splicing regulated by RBM10 8.62
Whole-Transcriptome Profiling of Canine and Human in Vitro Models Exposed to a G-Quadruplex Binding Small Molecule 8.61
Bladder cancer associated mutations in RXRA activate peroxisome proliferator-activated receptors 8.61
Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation 8.61
Transcriptome analysis of human lung epithelial cells 8.58
SRSF1 role in cellular gene expression and splicing 8.44
Glioblastoma stem cells infected by ZIKA virus 8.38
RNA-seq analysis of BORIS/CTCFL knockdown in K562 cell line 8.36
RNA-seq and small RNA-seq analysis of BORIS/CTCFL knockdown in K562 cell line 8.36
A Suv39H1-low chromatin state drives migratory cell populations in cervical cancer [RNA-Seq] 8.31
A Suv39H1-low chromatin state drives migratory cell populations in cervical cancer 8.31
Transcriptome analysis of human reninomas as an approach to understanding juxtaglomerular cell biology 8.17
PRDM1 inhibits proliferation of human colon cancer organoids 8.09
Transcriptome-wide analysis links the short-term expression of the b isoforms of T-cell intracellular antigens to protective proteostasis-mediated survival and quiescence 8.06
Transcriptome of EBV-infected gastric cancer cell lines 8.05
Generation of mature lung alveolar epithelial cells from human pluripotent stem cells 8.04
The role of FAM46C in myeloma cells 7.94
The role of FAM46C in myeloma cells [sequencing] 7.94
Nucleosome dynamics in human colorectal cancer specimens reveal activation of a CNOT3-regulated pathway of embryonic stem cell self-renewal 7.94
Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma [RNA-Seq; normal samples] 7.87
Identification of long noncoding RNAs regulated by p53 7.7
Waterpipe Smoking Induces Epigenetic Changes in the Small Airway Epithelium [RNA-Seq] 7.67
Waterpipe Smoking Induces Epigenetic Changes in the Small Airway Epithelium 7.67
Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells 7.63
Gene expression analysis of C4-2 cells treated with ACLY inhibitor and Enzalutamide 7.61
Expression profiles of restoration of BAP1 in a BAP1 deficient cell line 7.51
Transcriptome analysis of BAP1 knockout and restoration 7.51
The SPOP-containing Complex Functions as an E3 Ligase for SETD2 to Regulate Gene-Specific H3K36me3-Coupled Alternative Splicing 7.5
Comprehensive analysis of microRNA expression in regionalized human neural progenitor cells reveals microRNA-10 as a caudalizing factor 7.49
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-dependent Tumors 7.42
Evidence for HOXC6 as a potential molecular marker for non-small cell lung cancer 7.38
Gene expression profile of HGC27 and LMSU gastric cancer cell p53 KO and KD 7.36
Wnt addiction of genetically defined cancers reversed by PORCN inhibition 7.28
Identifying the molecular mode of action of itraconazole in colorectal cancer 7.25
Chronophin regulates metabolic and transcriptomic features of glioblastoma stem-like cells 7.23
RNA seq_A375 gSMARCB1 + A549 etoposide, Aurora kinases inhibitors treated 7.19
Gene induction by the USP6 oncogene in response to interferon 7.08
RNAseq of HEK293 cells after Chtop knockdown 7.08
Co-transcriptional loading of RNA export factors shapes the human transcriptome 7.08
24hr CA treatment vs. DMSO in HCT116 cells (from 'Identification of CDK8 and CDK19 substrates in human cells using cortistatin A and quantitative phosphoproteomics') 7.06
Next Generation Sequencing Facilitates Quantitative Analysis of Retinoblastoma Transcriptomes 6.94
Expression charcaterization of an internal protocol developed to differentiate RPE cells 6.92
RNA-seq of YB5 cells treated with Proscillaridin A 6.9
The ZZ-type zinc finger of ZZZ3 modulates the ATAC complex-mediated histone acetylation and gene activation 6.89
Loss of Function Mutations in ETS2 Repressor Factor (ERF) Reveal a Balance Between Positive and Negative ETS Factors Controlling Prostate Oncogenesis [22PC RNA-seq] 6.89
Ribosome profiling of TGFb-treated cells indicates reduced leucine availability 6.88
Lysine benzoylation is a novel histone mark [RNA-seq] 6.86
Lysine benzoylation is a novel histone mark 6.86
Cystathionine-β-Synthase Promotes Colon Carcinogenesis 6.77
Comparison of small cell lung cancer PDX model FHSC04 for response to LSD1 inhibitor RG6016/ORY1001 6.71
Paxillin regulates genomic networks in prostate cancer [LNCaP] 6.69
SRSF2 mutations impair hematopoiesis and alter exon recognition 6.67
Identification of diverse target RNAs that are functionally regulated by human Pumilio proteins 6.6
Effects of NSUN2 deficiency on the mRNA 5-methylcytosine modification and gene expression profile in HEK293 cells (RNA-Seq) 6.56
Novel kinase fusion oncogenes in post-Chernobyl radiation-induced pediatric thyroid cancers 6.55
Global transcriptome analysis of HAP1 cells 6.42
Single-cell RNA-Seq Investigation of Foveal and Peripheral Expression in the Human Retina 6.34
Image based identification and targeting of cancer stem cells in pancreatic adenocarcinoma (PDAC) 6.31
MOV10 Is a 5' to 3' RNA Helicase Contributing to UPF1 mRNA Target Degradation by Translocation along 3'UTRs (expression) 6.24
MOV10 Is a 5' to 3' RNA Helicase Contributing to UPF1 mRNA Target Degradation by Translocation along 3'UTRs 6.24
Alu RNA modulates the expression of cell cycle genes in human fibroblasts 6.2
Gene expression profile difference among renal location in a stone former 6.1
Transcriptome analysis of genetically matched human induced pluripotent stem cells disomic or trisomic for chromosome 21 6.08
Co-regulation of splicing by Rbfox1 and hnRNP M 5.97
Co-regulation of splicing by Rbfox1 and hnRNP M [hnRNPM k-d+Rbfox1 RNA-Seq] 5.97
Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression 5.96
Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression [RNA-Seq] 5.96
SIX4 acts as a master regulator of genes associated with the malignant phenotype of non-small cell lung cancer cells 5.95
RNA-seq and m6A-seq of AML cells with FTO knockdown or inhibition 5.91
Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer 5.9
Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer [RNA-Seq] 5.9
HuR controls apoptosis and activation response without effects on cytokine 3′ UTRs 5.87
RNAseq analysis of patient-derived luminal breast cancer xenografts treated with progestins 5.79
Patient-derived luminal breast cancer xenografts with progestins 5.79
RNA isoform screens reveal the essentiality and tumor suppressor activity of ultraconserved poison exons 5.78
Suppression of ribosomal pausing by eIF5A is necessary to maintain the fidelity of start codon selection 5.69
Suppression of ribosomal pausing by eIF5A is necessary to maintain the fidelity of start codon selection (RNA-sequencing) 5.69
RNA-Seq analysis of Head and Neck Squamous cell carcinoma cell-lines 5.64
Analysis of transcriptome changes following SOX2 knockdown in three different Ewing sarcoma cell lines 5.6
Distinct Roles of BET Family Members in ERα Enhancer Function and Gene Regulation in Breast Cancer Cells [RNA-seq] 5.58
Distinct Roles of BET Family Members in ERα Enhancer Function and Gene Regulation in Breast Cancer Cells 5.58
RNA-Seq in PWS iPSC-derived neurons 5.56
hMTR4 plays a central role in creating balanced nuclear RNA pools for degradation and export 5.54
OBESITY IS ASSOCIATED WITH IMPAIRED EXPRESSION OF THE GLYCOSYLTRANSFERASE EOGT IN DECIDUALIZING ENDOMETRIUM 5.54
Interactions of aCPs with Cytosine-rich Polypyrimidine Tracts Enhance Splicing of Cassette Exons 5.53
IDH3a KO RNA-seq 5.51
An atlas of TNF-α-responsive promoters and enhancers in the intestinal epithelial cell model Caco-2 5.49
HNRNPM-regulated splicing dependencies in prostate cancer [RNA-Seq] 5.45
HNRNPM-regulated splicing dependencies in prostate cancer 5.45
Transcriptomic profiling discloses molecular and cellular events related to neuronal differentiation in SH-SY5Y cells 5.45
The expression of genes encoding palmitoylated proteins in axonal and synaptic compartments is affected in CLN1/PPT1 transfected neuronal cells 5.43
DJ-1 is dispensable for human stem cell homeostasis 5.4
Cajal bodies are linked to genome conformation 5.37
Cajal bodies are linked to genome conformation [RNA-Seq] 5.37
Time-course expression data from HEK293∆RAF1:ER cells stimulated with 4OHT and labelled with 4SU 5.35
Time-course expression data from HEK293∆RAF1:ER cells stimulated with 4OHT, U0126, CYHX, ActD, EGF, FGF, or IGF and labelled with 4SU 5.35
N6-methyladenosine Recruits HNRNPG for Alternative Splicing Regulation 5.33
RNA Sequencing Analysis of villus tissues from unexplained recurrent spontaneous abortion patients and controls with induced abortions 5.32
Capturing the biology of mild versus severe disease in a pluripotent stem cell-based model of Familial Dysautonomia 5.23
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis 5.21
Next Generation Sequencing Facilitates Quantitative Analysis of Wild Type and SMAD4 Y95 Mutation Transcriptomes 5.17
Transcriptional profiling of CD45RO+CD57+CD4+ T cells 5.15
Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer 5.06
Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer (RNA-seq) 5.06
Genome-wide chromatin analysis of Ewing sarcoma (RNA-seq) 5.05
Genome-wide chromatin analysis of Ewing sarcoma 5.05
MUC1-C Drives Lineage Plasticity in Progression to Neuroendocrine Prostate Cancer 4.99
Paxillin regulates genomic networks in prostate cancer [C4-2] 4.98
Quiescent glioblastoma cells shift to an epithelial-mesenchymal transition-like gene program 4.91
Splicing function of mitotic regulators links R-loop mediated DNA damage to tumor cell killing 4.91
A NIK-SIX signaling axis controls inflammation by targeted silencing of noncanonical NF-κB 4.89
Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge 4.88
Differential RNA-seq analysis comparing APC-defective and APC-restored SW480 colorectal cancer cells 4.83
MicroRNA (miR)-211 loss promotes metabolic vulnerability and BRAF inhibitor sensitivity in melanoma 4.79
Molecular analysis of renal cell carcinoma with unclassfied histology 4.79
Molecular analysis of renal cell carcinoma with unclassfied histology [gene expression] 4.79
Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival 4.75
Nuclear import of the DSCAM-cytoplasmic domain drives signaling capable of inhibiting synapse formation 4.74
Transcriptome analysis in Neobractatin treated cells 4.73
Modeling the ESR1 tyrosine 537 mutation with CRISPR-Cas9 for mechanistic studies and evaluation of therapeutic approaches for metastatic breast cancer [RNA-Seq] 4.69
Modeling the ESR1 tyrosine 537 mutation with CRISPR-Cas9 for mechanistic studies and evaluation of therapeutic approaches for metastatic breast cancer 4.69
RG/RGG boxes are common binding motifs in RNA-G-quadruplex-interacting proteins 4.68
Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer 4.67
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L 4.65
Downregulation of LATS kinases alters p53 to promote cell migration 4.64
transcriptomic profiling of HEK293 cells upon individual knockdown of the splicing factors RBM17, U2SURP or CHERP 4.6
Neural cell adhesion molecule 1 (NCAM1; CD56) promotes leukemogenesis and confers drug resistance in acute myeloid leukemia. 4.58
Transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis [MultiDisease] 4.56
CDK12 catalytic activity is rate-limiting for RNAPII processivity on core DNA replication genes and G1/S progression 4.56
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors 4.55
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression 4.53
EIF1AX-A113 splice and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC 4.51
Understanding the reproducibility and robustness of the kidney organoid differentiation protocol using RNA-seq 4.5
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression 4.5
Role of FGFR1 in neuronal devlopment 4.45
Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration 4.41
Differential expression in wild-type and mutant neurofibroma and MPNST cell lines 4.34
Neurofibroma 4.34
An integrative network biology analysis identifies miR-508-3p as the determinant and a prognosis biomarker of the mesenchymal subtype ovarian cancer 4.34
The Polycomb protein BMI1 induces an invasive gene expression signature in melanoma that promotes metastasis and chemoresistance. 4.33
Genomic basis for clinical response to histone deacetylase inhibition in advanced urothelial carcinoma 4.31
Discovery of cis-spliced chimeric RNAs between adjacent genes in human prostate cells 4.3
CDK12 catalytic activity is rate-limiting for RNAPII processivity on core DNA replication genes and G1/S progression (nuclear RNA) 4.27
Replicated transcriptome profiling of Normal and Cancerous Prostate Cells [RNA-Seq] 4.26
Three-dimensional disorganisation of the cancer genome occurs coincident with long range genetic and epigenetic alterations 4.26
Three-dimensional disorganisation of the cancer genome occurs coincident with long range genetic and epigenetic alterations [RNA-seq] 4.26
RNAseq Analysis in glioblastoma cells treated with Mepazine 4.24
NHLRC1 re-expression in cancer cells 4.22
Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine resistant breast cancer [RNA-seq] 4.21
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine resistant breast cancer 4.21
Transcriptome profiling of Normal and Cancerous Prostate Cells 4.2
RNAseq Study in CC-671 Treated Cal-51 Cells 4.2
β-catenin/Tcf7l2 dependent transcriptional regulation of GLUT1 gene expression by Zic family proteins in colon cancer 4.19
RNA-seq Profiles in Transcription elongation factors are in vivo-specific cancer dependencies in glioma 4.17
Transcription elongation factors are in vivo-specific cancer dependencies in glioma 4.17
Investigsting the role of NF-ĸB p50 S80 phosphorylation in regulating TNFα-induced transcription in HEK293T cells 4.03
CD95L derived si- and shRNAs kill cancer cells through an RNAi mechanism by targeting survival genes [shL3.shR6.RNAseq.lg] 4.0
Transcriptomic analysis of trametinib-resistant HCT116 colorectal carcinoma cells compared to the parental control cells 3.96
Human gut derived-organoids as model to study gluten response and effects of microbiota bioproducts in celiac disease 3.92
AhR activity directs BRAF inhibitors resistance in metastastic melanoma 3.91
AR-independent prostate cancer is sustained through FGF signaling 3.88
Biochemical fractionation of HEK293 nuclei and RNA-seq of chromatin-associated and soluble-nuclear RNA 3.87
Gene expression profiling of papillary thyroid cancer from central and invasive regions 3.87
RNA sequencing of lncRNAs knockdown in human pancreatic cancer cell lines 3.86
The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia 3.85
Human pluripotent stem cell-derived brain tumor model uncovered embryonic stem cell signature as a key driver in atypical teratoid/rhabdoid tumor (RNA-Seq) 3.85
Cis-SAGe fusion RNAs in transcription splicing factors knocking-down 293T cells 3.83
Isolation and sequencing of AGO-bound RNAs reveals characteristics of stem-loop processing in vivo 3.83
Global Regulation of Alternative Internal Exon Usage by mRNA 3' End Formation Factors [RNA-Seq] 3.77
Global Promotion of Alternative Internal Exon Usage by mRNA 3' End Formation Factors 3.77
RNA-seq analysis of AML cells in response to ASLAN003 3.76
Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment 3.75
Large-scale epigenetic reprogramming is punctuated late during the evolution of pancreatic cancer progression 3.75
Neurofibromin is an Estrogen Receptor alpha Transcriptional Co-repressor in Breast cancer 3.72
Simultaneous detection and relative quantification of coding and non-coding RNA using a single sequencing reaction 3.71
Inhibition of ERG Activity in Patient Derived Prostate Cancer Xenografts using the Small Molecule Inhibitor YK-4-279 3.71
Perlman syndrome nuclease DIS3L2 controls cytoplasmic non-coding RNAs and provides surveillance pathway for maturing snRNAs 3.67
Evaluating and comparing the Transcriptome of (human) Hek 293 based cells, expressing either CHD3 or CHD4 3.65
Global transcriptional changes in the JJN3 myeloma cell line that occur as a result of treatment with 2 pyrrolobenzodiazepine (PBD) monomers 3.64
The role of the Calcium-Sensing receptor in colorectal cancer 3.57
Diarrhea in lymphocytic colitis: ERK1/2-dependent ENaC dysregulation and claudin-4-, -5- and -8-related barrier defects 3.57
Silencing p300 in MCF7 cells to study expression and alternative splicing 3.55
Dnmt3a and Dnmt3b associate with enhancers to regulate human epidermal stem cell homeostasis 3.5
Gene expression profile of HGC27 gastric cancer cell p53 KO and KD 3.47
AKT Inhibition Promotes Non-autonomous Cancer Cell Survival 3.46
AKT Inhibition Promotes Non-autonomous Cancer Cell Survival [RNA-Seq] 3.46
FOXA1 Chromatin Binding is Regulated by LSD1-Mediated Demethylation 3.46
RNA-Seq with DHT induction and/or GSK treatment at 24, 48 hrs and 2 weeks 3.46
Canonical poly(A) polymerase activity promotes the decay of a wide variety of mammalian nuclear RNAs 3.44
Whole-transcriptome profilings between a pair of HCA7-derived KRAS-wildtype cetuximab sensitive and resistant colon cancer cells from 3D culture 3.41
Identification of HOXB13 target genes responsive to BET inhibitors 3.41
JAK dependent survival of ALK- ALCL 3.39
Campylobacter concisus pathotypes induce distinct global responses in intestinal epithelial cells [UNSWCD] 3.33
Propargite, an environmental chemical, interacts with GWAS identified diabetes genes to impact human pancreatic β-cell death 3.29
Characterisation of HIF-dependent alternative isoforms in pancreatic cancer 3.22
Repression of stress-induced LINE-1 expression protects cancer cell populations from lethal drug-exposures [RNA-Seq] 3.19
Repression of stress-induced LINE-1 expression protects cancer cell populations from lethal drug-exposures 3.19
BRG1 governs Glucocorticoid Receptor interactions with chromatin and pioneer factors across the genome 3.18
LIN28A modulates splicing and gene expression programs in breast cancer cells [RNA-Seq] 3.18
LIN28A modulates splicing and gene expression programs in breast cancer cells 3.18
KMT2C medaites the estrogen dependence of breast cancer through regulation of ERα enhancer function 3.1
RNA-sequencing of the GSI treatment of the CUTLL1 cell line 3.05
Analysis of active enhancers and direct androgen receptor target genes in VCaP prostate cancer cells 3.05
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer 3.01
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer (RNA-Seq) 3.01
Gene expression profile in breast cancer cell lines using RNA sequencing 3.0
DHX15 regulates CMTR1-dependent gene expression and cell proliferation 3.0
Expression alterations induced by restoration of AXIN1 expression in SNU449 hepatocellular carcinoma cells 2.97
The Wnt/β-catenin and RAS-ERK Pathways were Activated in Tissues of Chemotherapy-Resistant Gastric Cancer PDX Tumor 2.96
DGCR8 acts as a novel adaptor for the exosome complex to degrade double-stranded structured RNAs 2.92
Next generation sequencing of advanced non-castrate prostate cancer treated with docetaxel chemotherapy 2.89
Transcriptional effect of ETV1 knockdown in melanoma cells 2.87
ELF1 expression in prostate cells reduces oncogenic ETS functions and promotes senescence and sensitivity to chemotherapy through distinct gene expression programs 2.85
ELF1 expression in prostate cells reduces oncogenic ETS functions and promotes senescence and sensitivity to chemotherapy through distinct gene expression programs [RNA-seq] 2.85
Chemotherapeutic drugs inhibiting Topoisomerase 1 activity inhibit TNF-induced inflammatory gene expression 2.83
Effect of SF3B1 suppression in cancer cells with different SF3B1 copy-number levels 2.82
Cooperation of GRSF1 and the mitochondrial degradosome (hSuv3-PNPase complex) in degradation of mitochondrial RNA 2.8
The cohesin release factor WAPL restricts chromatin loop extension. 2.68
The cohesin release factor WAPL restricts chromatin loop extension. [RNA-Seq] 2.68
Thymine DNA Glycosylase as a novel target for melanoma: effect of TDG silencing on gene expression in SK-mel-28 melanoma cells 2.65
Expression profiling by high throughput sequencing of tumors derived from human prostate epithelial cells transformed with the oncogenes N-Myc and myrAKT1. 2.65
IKZF1 as a Master Regulator of Immune Infiltrate Recruitment in Solid Tumors 2.63
Pluripotent stem cell model of Nakajo-Nishimura syndrome untangles proinflammatory pathways mediated by oxidative stress 2.62
A runaway PRH/HHEX-Notch3 feedback loop drives cholangiocarcinoma (RNA-Seq) 2.62
CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer 2.62
LEDGF and HDGF2, histone H3K36 methyl-binding proteins that assist RNA polymerase II transcription through nucleosomes 2.61
An Argonaute phosphorylation cycle promotes microRNA-mediated silencing [polyA RNA-seq] 2.61
Non-coding and coding transcriptional profiles are significantly altered in pediatric Retinoblastoma tumors 2.59
Transcription factor p63 bookmarks genomic loci in epithelial cells and regulates a subset of target genes during epidermal differentiation through dynamic enhancers 2.58
Transcription factor p63 bookmarks genomic loci in epithelial cells and regulates a subset of target genes during epidermal differentiation through dynamic enhancers (RNA-Seq) 2.58
FMRP-associated MOV10 facilitates and antagonizes miRNA-mediated regulation 2.57
RNA sequencing to study transcriptomic changes in DLD-1 (colorectal adenocarcinoma) cells exposed to soft polyacrylamide matrices (~2 kPa and ~55 kPa) for short time scale of 90 minutes 2.57
RNA-Seq analysis of JIB-04 effects on global cellular transcription and HIV in 2D10 T cells 2.56
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 2.51
Bioreactor-engineered cancer tissues mimic phenotypes, gene expression profiles and drug resistance mechanisms detectable in xenografts and clinical specimens. 2.5
PTBP1 excludes UPF1 to protect long 3'UTRs from nonsense-mediated mRNA decay 2.5
NEUROD1 dependent gene regulation in murine pancreatic endocrine cells and human stem cell derived insulin producing cells 2.49
Rna-seq transcriptome data for insulin-GFP+ cells differentiated from NEUROD1 knock out and NEUROD1+/+ control human embryonic stem cells. 2.49
Effect of ILF3 depletion in HeLa cells on RNA steady state levels 2.49
Transcriptomics profiling of Alzheimer’s disease reveal novel molecular targets 2.49
RNA-seq of HDAC2-disrupted 293FT cells by CRISPR-Cas9 2.48
RNA-seq in endometrial stromal tumors 2.44
m6A-dependent regulation of messenger RNA stability 2.43
Mechanism suppressing H3K9 trimethylation in pluripotent stem cells and its demise by polyQ-expanded huntingtin mutations [RNA-seq] 2.42
Mechanism suppressing H3K9 trimethylation in pluripotent stem cells and its demise by polyQ-expanded huntingtin mutations 2.42
Diarrhoeal mechanisms of the Campylobacter jejuni enteritis 2.42
Somatic cell fusions reveal extensive heterogeneity in basal-like breast cancer 2.41
Somatic cell fusions reveal extensive heterogeneity in basal-like breast cancer [RNA-Seq] 2.41
Determining effects of microbial metabolite, Urolithin A on colon epithelial cells 2.38
RNA profiling Analysis of the Serum Exosomes Derived from Active and Latent M.tuberculosis infectious Patients 2.38
DDX54 regulates transcriptome dynamics during DNA damage response [RNA-seq2] 2.36
TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality 2.36
RNA Missplicing in Fuchs Endothelial Corneal Dystrophy 2.35
Illumina Human Polycystic Liver Disease and Normal Biliary Stem Cell RNAseq 2.35
RNA-sequencing of mRNAs from control and CAP-D3 deficient Salmonella infected HT-29 cells 2.35
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L [RNA-Seq KO] 2.35
Proteomics identifies a marker signature of MAPKi resistance in melanoma 2.34
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia 2.34
Patient Derived Xenograft for Delivery of Precision Medicine in Castrate Resistant Prostate Cancer 2.33
Contribution of SRF and Nkx2-5 to androgen-dependent gene expression in prostate cancer 2.33
Self-organized cerebral organoids with human specific features predict effective drugs to combat Zika virus infection 2.32
Self-organized cerebral organoids with human specific features predict effective drugs to combat Zika virus infection [RNA-seq] 2.32
Altered mRNA splicing by mutant p53 activates oncogenic RAS in pancreatic cancer 2.28
Next Generation Sequencing Facilitates Quantitative Analysis of UVB(20mJ/cm2 and 40mJ/cm2) exposed and untreated HaCaT keratinocytes Transcriptomes 2.28
EZH1/SUZ12 complex positively regulates the transcription of NF-κB target genes via interaction with UXT 2.27
U2AF1 mutations alter splice site recognition in hematological malignancies 2.24
JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML 2.24
Small molecule inhibition of ERK dimerization prevents tumorigenesis by Ras-ERK pathway oncogenes 2.18
CD86 regulates a pro-survival signal in myeloma cells 2.17
Lung adenocarcinoma metastasis is suppressed by the alveolar lineage transcription factors GATA6 and HOPX. 2.16
Pre-mRNA Splicing is Facilitated by an Optimal RNA Polymerase II Elongation Rate 2.15
Targetting super enhancer associated oncogenes in esophageal squamous cell carcinoma 2.14
Targetting super enhancer associated oncogenes in esophageal squamous cell carcinoma [RNA-seq] 2.14
H1609088 Human RNA-Sequencing 2.12
A20 regulates canonical wnt-signaling through an interaction with RIPK4 2.09
Genes altered in expression by Cisplatin treatment in lung cancer cell lines 2.08
RNA-seq analysis of PRMT5-regulated genes in irradiated/non-irradiated LNCaP cells 2.08
miR941 overexpression experiment 2.04
Genome-wide RNA-sequencing (RNA-seq) of benign and malignant prostate cell lines without and with androgen (R1881) stimulation. 2.02
RNA-Sequencing experiment for effects of PKF115-584 treatment on four T-ALL cell lines (RPMI8402, HPB-ALL, Jurkat, CCRF-CEM). 1.98
Transcriptional changes in pancreatic cancer cells associated with gemcitabine resistance 1.92
Kidney compartment specific eQTL studies highlight causal genes and pathways for renal disease development 1.91
JUNB is a critical AP1 component for SMAD2/3 binding after TGFβ stimulation [RNA-seq] 1.91
SMAD2/3 are redirected to novel sites in MCF10A MII after prolonged TGFβ stimulation 1.91
Expression profiling of lncRNAs, miRNAs and mRNAs and their differential expression in leiomyoma using next generation RNA sequencing 1.89
RNA sequencing of human pancreatic cancer cell lines 1.89
Transcriptome analysis of V336Y mutant mitochondrial ribosomal protein in human HEK293 cell line 1.83
The MEF2B Regulatory Network 1.82
The MEF2B Regulatory Network - RNA-seq data 1.82
Gene expression analysis of human adenomas. 1.79
DHX9 suppresses spurious RNA processing defects originating from the Alu invasion of the human genome [uvCLAP CLIP-seq] 1.78
Ribosomal protein RPL26 is the principal target of UFMylation 1.76
Transcriptome wide identification of Dicer binding in human and C. elegans reveals a variety of substrates 1.74
Differential Protein Occupancy Profiling of the mRNA Transcriptome 1.73
RNA-Seq analysis of prostate cancer cell line LNCaP treated with vehicle, androgen, androgen and IMTPPE, androgen and JJ-(+)-450, androgen and JJ-(-)450, androgen and enzalutamide 1.67
Activation of the p53 transcriptional program sensitizes cancer cells to Cdk7 inhibitors 1.65
Functional significance of the HIV-1 Tat signature amino acid residues 1.64
mRNA sequencing of the global effect of SOX2 on gene expression in hESC and hESC derived NPCs. 1.58
Cerebral Organoids Recapitulate Epigenomic Signatures of the Human Fetal Brain 1.5
RNAseq of T-ALL upon long non coding rna purturbation 1.5
SMYD2 specificly regulate BIX-01294 induced TP53 target genes revealed by RNA-Seq 1.49
RNA sequencing of prostate cancers reveal insights on the prognostic significance of visibility on multi-parametric MRI 1.39
Hsa-miR-139-5p/HNRNPF axis modulates gene-transcripts balance in thyroid cancer cells 1.39
Effects of Inhibition of CDK8/19 Mediator Kinase by Senexin B in HEK293 cells treated with or without TNF-alpha 1.37
β-Caryophyllene Enhances the Transcriptional Upregulation of SREBP-dependent Lipid Biosynthesis in Breast Cancer Cells 1.3
RNA-seq of HEK293T cells overexpressing TET1-FL or TET1-ALT 1.29
Single-cell Transcriptomic Atlas of the Human Retina Identifies Cell Types Associated with Age-Related Macular Degeneration 1.29
Evaluation of the immunogenicity of live-attenuated influenza vaccines in nasal epithelial cells in primary differentiated human nasal epithelial cells [RNA-Seq] 1.28
Evaluation of the immunogenicity of live-attenuated influenza vaccines in nasal epithelial cells in primary differentiated human nasal epithelial cells 1.28
Comparison of 7 small cell lung cancer PDX models, cultured ex vivo, for response to LSD1 inhibitor RG6016/ORY1001 1.27
Anaylsis of the effect of down-regulation of the EWS-FLI1 fusion protein in Ewing Sarcoma cells by RNA-seq. 1.26
Next Generation Sequencing Facilitates Quantitative Analysis of SW480 cells and HPSE-knockdown SW480 cells Transcriptomes 1.24
HDAC and NFκB antagonists synergistically inhibit growth and metastatic dissemination of MYC-driven medulloblastoma 1.24
An intramolecular salt bridge linking TDP43’s RNA recognition motifs dictates RNA binding, protein stability and TDP43-dependent neurodegeneration 1.23
Gene expression profiling of patient's DCIS-IDC tandem lesions by RNA sequencing analysis 1.21
Endometrial transcriptome and PGR cistrome in cycling fertile women [RNA-seq] 1.19
Endometrial transcriptome and PGR cistrome in cycling fertile women 1.19
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. 1.19
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. 1.19
Effect of estrogen (E2) treatment on the C4-12 relative to the MCF7 cells 1.17
Global reduction in H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas 1.15
Genome-wide modelling of transcription kinetics reveals patterns of RNA processing delays 1.13
Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance 1.11
Transcriptomics profiles of patient-matched normal kidney and ccRCC pairs 1.1
Sequencing of ponatinib-resistant LC-2/ad derivatives (PR1 and PR2) and parental LC-2/ad cells 1.1
Identification of microRNA-dependent gene regulatory networks driving human pancreatic endocrine cell differentiation [RNA-Seq III] 1.08
Epigenetic changes induced by Bacteroides fragilis toxin (BFT) [RNA-seq] 1.06
Epigenetic changes induced by Bacteroides fragilis toxin (BFT) 1.06
Activating Transcription Factor 4 modulated TGFb-induced aggresiveness in triple negative breast cancer vis SMAD2/3/4 and mTORC2 signaling 1.05
Tunable protein synthesis by transcript isoforms in human cells (Transcript Isoforms in Polysomes sequencing: TrIP-seq) 1.02
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer 1.01
HSB-2 cells stably expressing LDB1 or mutant LDB1 proteins 0.98
A MYC/GCN2/eIF2alpha negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer 0.96
RNA-Seq identifies condition-specific biological signatures of ischemia-reperfusion injury in the human kidney 0.94
The IMiDs, through loss of Ikaros and Aiolos, primes myeloma cells for daratumumab mediated killing by upregulation of CD38 0.93
Single-cell Transcriptomic Atlas of the Human Retina Identifies Cell Types Associated with Age-Related Macular Degeneration [Microfluidics] 0.86
Evolution of an lncRNA leads to a primate specific modulation of alternative splicing 0.84
KSDM1b Role in Ewing Sarcoma 0.84
Identification of long noncoding RNAs in T-ALL cell lines 0.83
The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma [RNA-Seq Tumor] 0.81
Bi-allelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney 0.8
Gene expression in PANC-1 and AsPC-1 human pancreatic carcinoma cells under hypoxia, nutrient starvation and low pH culture condition. 0.8
PANC-1 and AsPC-1 human pancreatic carcinoma cells under hypoxia, nutrient starvation and low pH culture condition 0.8
Human antimicrobial cytotoxic T lymphocytes, defined by NK receptors and antimicrobial proteins, kill intracellular bacteria 0.79
Interactome (iCLIP) and Translatome ( Polysome profiling) of Musashi 2 (MSI2) targets in K562 0.79
Low H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas 0.74
RNA-seq of three Ewing sarcoma cell lines (A673, SK-N-MC, RDES), transfected with either siControl or siMYBL2. 0.74
Cooperation of dominant oncogenes with regulatory variants shapes clinical outcomes in pediatric cancer 0.74
Role of COP1 on MAP kinase transcriptional output in gastrointestinal stromal tumor 0.73
Xrn2 accelerates termination by RNA polymerase II, which is underpinned by CPSF73 activity 0.72
TrapSeq: An RNA Sequencing-based pipeline for the identification of genetrap insertions in mammalian cells 0.72
Integration of kinase and calcium signaling at the level of chromatin underlines inducible gene activation in T cells 0.7
Gene expression analysis upon mtDNA depletion 0.7
Gene expression analysis upon mtDNA depletion [RNA-seq] 0.7
Effect on small molecule RBPJ inhibitor (RIN1) on gene expression in Jurkat cells compared to gamma secretase inhibition and siRNA knockdown of RBPJ 0.68
RNA sequencing of lesional and nonlesional skin from patients with atopic dermatitis 0.65
Transcriptional dependencies in diffuse intrinsic pontine glioma 0.61
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (LNCaP RNA-seq) 0.61
O-GlcNAc transferase fine-tunes MYC-dependent transcription to promote cell cycle [RNA-seq] 0.6
O-GlcNAc transferase fine-tunes MYC-dependent transcription to promote cell cycle 0.6
Genomic profiling of biliary tract cancer cell lines reveals molecular subtypes and actionable drug targets 0.59
Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition [RNA-Seq] 0.57
Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition 0.57
hMTR4 plays a central role in creating balanced nuclear RNA pools for degradation and export II 0.56
RNA-seq in neurons derived from iPSCs in controls and patients with schizophrenia and 22q11 del 0.55
Pomalidomide inhibits PD-L1 induction to promote anti-tumor immunity 0.55
Loss of endometrial plasticity in recurrent pregnancy loss (RNA-Seq) 0.51
Loss of endometrial plasticity in recurrent pregnancy loss 0.51
RNA seq with AML (NB4) cells upon FTO inhibition 0.48
Tracing Enhancer Networks using Epigenetic Traits (TENET) 0.45
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma 0.41
Apoptosis enhancing drugs overcome innate platinum resistance in CA125 negative tumor initiating populations of high grade serous ovarian cancer 0.39
Mutant KRAS/BRAF Reprograms the Enhancer Landscape via GATA1 to Drive Chemoresistance 0.36
Effect of FGF13 depletion on the H460 cell line 0.36
Methylome, hydroxymethylome, and integrative transcriptome profiling in human CRC tissue and paired normal tissues 0.35
Transcriptome analysis upon C6orf203 silencing 0.35
A SRp55-regulated alternative splicing network controls pancreatic beta cell survival and function 0.34
Transcriptome analysis of VCaP xenografts resistant to dual therapy with abiraterone and enzalutamide 0.33
Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny 0.33
Transcriptome-analysis of patient-derived normal and ulcerative colitis intestinal epithelial organoids 0.33
Comparative Analysis of Cas9 Activators Across Multiple Species 0.3
Reducing the structure bias of RNA-Seq reveals a large number of non-annotated non-coding RNA 0.26
Finding missing proteins from epigenetically manipulated human cells 0.22
Efficient and precise editing of endogenous transcripts with SNAP-tagged ADARs 0.22
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells 0.2
Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify 0.18
Defective transcription elongation in a subset of cancers confers immunotherapy resistance (BGI12 RNA-Seq) 0.17
The secretome of skin cancer cells activates the mTOR/MYC pathway in healthy keratinocytes and converts them into tumorigenic cells 0.13
A Low-cost Multiplex Biomarker Assay Stratifies Colorectal Cancer Patient Samples into Clinically-relevant Subtypes 0.13
A Low-cost Multiplex Biomarker Assay Stratifies Colorectal Cancer Patient Samples into Clinically-relevant Subtypes: Singapore Cohort RNA-seq 0.13
Genome-wide mapping of DROSHA cleavage sites on primary microRNAs and novel substrates [RNA-seq] 0.11
Genome-wide mapping of DROSHA cleavage sites on primary microRNAs and novel substrates 0.11
RNA deep sequencing analysis of glioma stem cells(GSCs) and non-GSCs 0.09
HEK293 TFAM Knockout Expression Study 0.07
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors 0.05
eRNA: A graphic user interface-based tool for RNA sequencing data analysis [mRNA-Seq] 0.05
eRNA: A graphic user interface-based tool for RNA sequencing data analysis 0.05
Profiling gene expression changes in primary ovarian tumors compared to matched normal fallopian tubes 0.05
RNA sequencing of isogenic BRCA2 haploinsufficient vs. wild-type T-ALL cells 0.03
RNA-Seq Analysis in purified iPS cell-derived neuronal samples 0.03
Age-Related Gene Expression Changes in Prostate Cancer Patients 0.02
Age-Related Gene Expression Changes in Prostate Cancer Patients [RNA-Seq] 0.02
RNA-seq analysis in knockdown Jurkat samples for each factor of TAL1 complex 0.02
Oncogenic roles of ARID5B in T-ALL 0.02
RNA-seq of cancer cell lines treated with T-025 0.01
Transcriptomic Analysis Of circRNAs/miRNAs/mRNAs upon Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection 0.01
RNA-Seq analysis of human colorectal cancer with liver metastasis 0.0


Contact Us

For scientific and technical queries contact Butte Lab @UCSF


Cite GENEVA Tool

Manuscript in Preparation